TNF superfamily in inflammatory disease: Translating basic insights

Trends in Immunology

Volumn 33, Issue 3, 2012, Pages 144-152

  Croft, Michael ^a   Duan, Wei ^a   Choi, Heonsik ^a   Eun, So Young ^a   Madireddi, Shravan ^a   Mehta, Amit ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CD134 ANTIGEN; CD30 ANTIGEN; CD30 LIGAND; CD70 ANTIGEN; DEATH RECEPTOR 3; HERPESVIRUS ENTRY MEDIATOR; OX40 LIGAND; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR LIKE FACTOR 1A; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; HERPES VIRUS; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; LYMPHOCYTE ACTIVATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; VIRUS ENTRY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; LIGANDS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 84857687171     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.10.004     Document Type: Review

References (79)

1. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 2009, 9:271-285.
2. Tansey M.G., Szymkowski D.E. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov. Today 2009, 14:1082-1088.
3. Salek-Ardakani S., Croft M. Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity. J. Interferon Cytokine Res. 2010, 30:205-218.
4. Vinay D.S., Kwon B.S. The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin. Exp. Immunol. 2011, 164:145-157.
5. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 2010, 28:57-78.
6. Siddiqui S., et al. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 2010, 137:797-804.
7. Karulf M., et al. OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J. Immunol. 2010, 185:4856-4862.
8. Zhang Z., et al. Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis. Am. J. Pathol. 2010, 177:2912-2920.
9. Fousteri G., et al. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J. Autoimmun. 2011, 36:210-220.
10. Cunninghame Graham D.S., et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat. Genet. 2008, 40:83-89.
11. Delgado-Vega A.M., et al. Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus. Genes Immun. 2009, 10:248-253.
12. Chang Y.K., et al. Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun. 2009, 10:414-420.
13. Dolff S., et al. Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:R150.
14. Gourh P., et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann. Rheum. Dis. 2010, 69:550-555.
15. Oflazoglu E., et al. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv. Exp. Med. Biol. 2009, 647:174-185.
16. Sun X., et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J. Immunol. 2010, 185:7671-7680.
17. Sun X., et al. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 2008, 134:447-458.
18. Dong L., et al. Increased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in systemic lupus erythematosus patients. J. Biomed. Biotechnol. 2010, 2010:569053.
19. Carvalho R.F., et al. CD153 in rheumatoid arthritis: detection of a soluble form in serum and synovial fluid, and expression by mast cells in the rheumatic synovium. J. Rheumatol. 2009, 36:501-507.
20. Gerli R., et al. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30. J. Rheumatol. 2008, 35:14-19.
21. Peters A.L., et al. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 2009, 21:293-300.
22. Australia and New Zealand Multiple Sclerosis Genetics Consortium Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 2009, 41:824-828.
23. Raychaudhuri S., et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat. Genet. 2008, 40:1216-1223.
24. Orozco G., et al. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann. Rheum. Dis. 2010, 69:813-816.
25. Blanco-Kelly F., et al. CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. PLoS ONE 2010, 5:e11520.
26. Lievens D., et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010, 116:4317-4327.
27. Poggi M., et al. The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia 2009, 52:1152-1163.
28. Missiou A., et al. CD40L induces inflammation and adipogenesis in adipose cells-a potential link between metabolic and cardiovascular disease. Thromb. Haemost. 2010, 103:788-796.
29. Ait-ghezala G., et al. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine 2008, 44:283-287.
30. Lincecum J.M., et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat. Genet. 2010, 42:392-399.
31. Komura K., et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann. Rheum. Dis. 2008, 67:867-872.
32. Olofsson P.S., et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008, 117:1292-1301.
33. Jeon H.J., et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010, 121:1124-1133.
34. Haga T., et al. Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway. J. Mol. Cell. Cardiol. 2009, 46:719-727.
35. Kim C.S., et al. The immune signaling molecule 4-1BB stimulation reduces adiposity, insulin resistance, and hepatosteatosis in obese mice. Endocrinology 2010, 151:4725-4735.
36. Nguyen Q.T., et al. Blockade of CD137 signaling counteracts polymicrobial sepsis induced by cecal ligation and puncture. Infect. Immun. 2009, 77:3932-3938.
37. Xia R., et al. TNFSF9 expression in primary biliary cirrhosis and its clinical significance. Cytokine 2010, 50:311-316.
38. Nolte M.A., et al. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 2009, 229:216-231.
39. Oflazoglu E., et al. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J. Immunol. 2009, 183:3770-3777.
40. Manocha M., et al. Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. J. Immunol. 2009, 183:270-276.
41. Yanagisawa S., et al. Effects of anti-CD70 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease. Brain Res. 2010, 1317:236-245.
42. Kawamura T., et al. CD70 Is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses. J. Invest. Dermatol. 2011, 131:1252-1261.
43. Behrendt A.K., Hansen G. CD27 costimulation is not critical for the development of asthma and respiratory tolerance in a murine model. Immunol. Lett. 2010, 133:19-27.
44. Sumi T., et al. CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice. Immunol. Lett. 2008, 119:91-96.
45. Browning J.L. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol. Rev. 2008, 223:202-220.
46. Chiang E.Y., et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 2009, 15:766-773.
47. Steinberg M.W., et al. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin. Immunopathol. 2009, 31:207-221.
48. Steinberg M.W., et al. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J. Exp. Med. 2008, 205:1463-1476.
49. Murphy T.L., Murphy K.M. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 2010, 28:389-411.
50. Pierer M., et al. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J. Immunol. 2009, 182:3139-3145.
51. Otterdal K., et al. Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation. Am. J. Respir. Crit. Care Med. 2008, 177:202-207.
52. Hastie A.T., et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J. Allergy Clin. Immunol. 2010, 125:1028-1036.
53. Doherty T.A., et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat. Med. 2011, 17:596-603.
54. Soroosh P., et al. Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. J. Exp. Med. 2011, 208:797-809.
55. Bassols J., et al. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity (Silver Spring) 2010, 18:239-246.
56. Kim H.J., et al. HVEM-deficient mice fed a high-fat diet are protected from adipose tissue inflammation and glucose intolerance. FEBS Lett. 2011, 585:2285-2290.
57. Tremelling M., et al. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm. Bowel Dis. 2008, 14:733-737.
58. Haritunians T., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm. Bowel Dis. 2010, 16:1830-1840.
59. Latiano A., et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an italian cohort of patients. PLoS ONE 2011, 6:e22688.
60. Meylan F., et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011, 4:172-185.
61. Shih D.Q., et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS ONE 2011, 6:e16090.
62. Meylan F., et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008, 29:79-89.
63. Pappu B.P., et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J. Exp. Med. 2008, 205:1049-1062.
64. Bull M.J., et al. The death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J. Exp. Med. 2008, 205:2457-2464.
65. Zhang J., et al. Role of TL1A in the pathogenesis of rheumatoid arthritis. J. Immunol. 2009, 183:5350-5357.
66. Fang L., et al. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J. Exp. Med. 2008, 205:1037-1048.
67. Nocentini G., Riccardi C. GITR: a modulator of immune response and inflammation. Adv. Exp. Med. Biol. 2009, 647:156-173.
68. You S., et al. Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS ONE 2009, 4:e7848.
69. Galuppo M., et al. The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice. Br. J. Pharmacol. 2011, 162:1186-1201.
70. Nocentini G., et al. Glucocorticoid-induced tumor necrosis factor receptor-related (GITR)-Fc fusion protein inhibits GITR triggering and protects from the inflammatory response after spinal cord injury. Mol. Pharmacol. 2008, 73:1610-1621.
71. Tomizawa R., et al. Association of functional GITR gene polymorphisms related to expression of glucocorticoid-induced tumour necrosis factor-receptor (GITR) molecules with prognosis of autoimmune thyroid disease. Clin. Exp. Immunol. 2011, 165:141-147.
72. Mackay F., Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 2009, 9:491-502.
73. Xiao Y., et al. APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur. J. Immunol. 2008, 38:3450-3458.
74. Lai Kwan Lam Q., et al. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14993-14998.
75. Zhu X.J., et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009, 114:5362-5367.
76. Bilsborough J., et al. TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma. Clin. Exp. Allergy 2008, 38:1959-1968.
77. Jiang C., et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J. Immunol. 2011, 186:6136-6147.
78. Kim S.S., et al. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J. Neurol. Sci. 2011, 306:9-15.
79. Hartung H.P., Kieseier B.C. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 2010, 3:205-216.